The University of British Columbia
UBC - A Place of Mind
The University of British Columbia
Faculty of MedicineDepartment of Biochemistry & Molecular Biology
  • Home
  • About
    • History
    • Staff
    • News
    • Alumni
    • BIOCAPS Spotlight
    • Contact Us
  • Faculty and Research
    • Faculty
    • Research
  • Undergraduate
    • Prospective Students
    • Current Students
    • Advising
    • Undergraduate Opportunities
  • Graduate
    • Prospective Students
    • Current Students
    • BMB-GSA
  • Postdocs
    • Postdoctoral Scholar Program
    • Post Doctoral Fellow Award
  • Seminars & Events
  • EDI
    • Astell Award
    • Mentorship Program
    • Work Learn Program
  • Resources
    • Workday Tutorials
    • Documents
    • Faculty Onboarding
    • Postdoctoral Fellows Onboarding
    • Research Associates Onboarding
    • IT Support
  • Careers
» Faculty of Medicine » Home » Dr. Pieter Cullis featured in Nature story on pivotal contributions to mRNA vaccines for COVID-19

Dr. Pieter Cullis featured in Nature story on pivotal contributions to mRNA vaccines for COVID-19

Posted on September 16, 2021

“The tangled history of mRNA vaccines,” a news feature published today in Nature, reflects on the culmination of work by hundreds of scientists who worked on mRNA vaccines for decades before the coronavirus pandemic brought a breakthrough.Former LSI Director Pieter Cullis is featured for his linchpin contributions in lipid nanoparticles (LNPs). “Many experts highlight another innovation that was crucial for mRNA vaccines — one that has nothing to do with the mRNA,” writes science journalist Elie Dolgin. “It is the tiny fat bubbles known as lipid nanoparticles, or LNPs, that protect the mRNA and shuttle it into cells.

“This technology comes from the laboratory of Pieter Cullis, a biochemist at the University of British Columbia in Vancouver, Canada, and several companies that he founded or led. Beginning in the late 1990s, they pioneered LNPs for delivering strands of nucleic acids that silence gene activity. One such treatment, patisiran, is now approved for a rare inherited disease.”

Read the full story via Nature online

Listen to Dr. Cullis discuss his LNP discoveries and vaccines of the future in an interview with CBC’s Quirks and Quarks

Find the original post on the LSC Website.

Read More | No Comments

  • Previous
  • Next
Department of Biochemistry & Molecular Biology
Faculty of Medicine
Life Sciences Centre
2350 Health Sciences Mall
Vancouver, BC Canada V6T 1Z3
Website biochem.ubc.ca
Find us on
  
Back to top
The University of British Columbia
  • Emergency Procedures |
  • Terms of Use |
  • Copyright |
  • Accessibility